Understanding CRISPRMorning ConsultThe use of CRISPR on non-viable human embryos has sparked a sense of urgency in the scientific community. In reaction, an international summit was hosted in December 2015 by the U.S. National Academy of Sciences, the … Continue reading
STAT |
There’s only one approved CAR–T, but companies are ready to capitalize on it
STAT AR-T is having a moment. Novartis (NVS 1) won the first Food and Drug Administration approval 2 in August for this class of personalized cancer treatments, beating rivals in the race 3 to sell a therapy that is custom-made with individual patients’ cells. |
|
Syncona’s Autolus begins three T–cell cancer trials
DIGITALLOOK The second most commonly diagnosed blood cancer after non-Hodgkin lymphoma, multiple myeloma is a blood cancer affecting plasma cells which can currently be treated but not cured. AUTO2 is the first dual-targeting CAR–T cell therapy in clinical … Arix Bioscience notes positive progress by AutolusStock Market Wire |
|
FDA puts hold on clinical trials for CAR–T cell therapy
BSA bureau (press release) Juno attributed the deaths to the interaction between the pre-conditioning chemo regimen —consisting of fludarabine and cyclophosphamide — and the CAR–T cells reinfused back into the patient. Cellectis and Juno have fallen behind other CAR-T … |
BU Today |
Kilachand Center Hosts Inaugural Symposium
BU Today Researchers in Khalil’s field of synthetic biology have “gotten really good at cataloging, gotten really good at disassembling” biological systems, he says, but not so good at the next step: assembling biological parts into functional tools or organisms. |
BU Today |
Kilachand Center Hosts Inaugural Symposium
BU Today Researchers in Khalil’s field of synthetic biology have “gotten really good at cataloging, gotten really good at disassembling” biological systems, he says, but not so good at the next step: assembling biological parts into functional tools or organisms. |